Project Overview

We are seeking a qualified and experienced external researcher for the Joint Action project focused on Cancer Screening (WP5). The project, which began 22 months ago, aims to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancer, as well as investigate implementation of screening programmes for lung, prostate and stomach cancer. Cancer represents a significant portion of the disease burden in Europe, much of which is preventable.

Cancer Risk Factors

The EUCanScreen project is designed to address this challenge by supporting strategies and policies that aim to reduce the burden of cancer, focusing on both personal and societal risk factors. The Europe’s Beating Cancer Plan has called for a new EU-Supported Cancer Screening Scheme to ensure high performance of cancer screening programmes across all Member States (MS). The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programmes – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.

Senior Expert

The senior expert should have a PhD or LLM in law and extensive experience in data protection, health data governance and ELSI aspects of data‑driven health research, with a substantial part of this experience acquired in European collaborative projects in the biomedical field. The expert is expected to be knowledgeable about compliance, responsible data use, and EU and national frameworks in oncology.

Key Responsibilities

Main task:

The main task will involve quality assurance and analysis of the legal and ethical framework related to an already conducted cross-European survey. This task requires outstanding legal qualifications, with a particular focus on Spanish law across the Spanish health regions. The task will furthermore involve cross-European data analysis, requiring excellent knowledge of EU health data legislation and plans.

Assessment of data‑driven cancer projects:

The expert must demonstrate solid experience in assessing large‑scale health research projects based on cancer data, including federated repositories and multi‑centre or cross‑border infrastructures. This includes designing and applying risk analysis methods, DPIAs and broader data governance assessments that are tailored to cancer use cases (e.g. longitudinal data collections, multi‑modal data integration, secondary use of cancer data). The expert should be able to translate these assessments into recommendations that can be adopted by hospital partners, research centres and industry within the consortium.

ELSI framework for cancer data sharing:

The role requires proven ability to design, implement and monitor ELSI frameworks specifically adapted to cancer screening research and innovation. This includes defining ethical and legal governance arrangements for data acquisition, annotation, sharing and reuse. The expert should be able to communicate with ethics committees, data protection officers and clinical governance bodies as needed, and to provide clear, practical recommendations.

Expertise on European projects and EHDS‑relevant initiatives:

The senior expert should have a track record of participation in, or support to, European research and innovation projects in the area of oncology or health data platforms, ideally including roles in ELSI, data governance or regulatory work packages. Experience with pan‑European repositories or federated infrastructures built under EU‑funded initiatives is particularly relevant. The expert should also be familiar with the evolving framework for European data spaces and the European Health Data Space, and able to operationalise concepts such as secure processing environments, data altruism and cross‑border secondary use of imaging data in the context of European projects.

Governmental, institutional and multi‑stakeholder support:

The expert is expected to bring experience in advising or supporting public authorities, regulatory bodies or professional societies on issues related to digital health or health data governance. This may involve experience from participation in expert groups or advisory boards at national or European level, as well as contributions to guidelines or model frameworks for the use of health data in research and clinical practice. Experience in accompanying universities, research hospitals and innovation hubs in the implementation of compliance models and governance structures for cancer projects, including training and capacity‑building activities for clinicians, researchers and technical staff, is considered an asset.

Qualifications and Requirements

• Advanced academic qualifications, including a PhD or LLM, in law. As a substantial amount of the legal research will focus on Spain, applicants with a Spanish law degree will be prioritized.
• Experience from large-scale, collaborative EU funded projects (e.g., Horizon Europe, Erasmus+, FP7).
• Proven ability to deliver projects within scope, budget, and timeline constraints.
• Strong record of working with cross-functional, multinational teams, including academics, technologists, and policymakers, ensuring effective communication and project execution.
• Full professional proficiency in English (C2 level), enabling effective communication, reporting, and stakeholder engagement.
• Experience in preparing comprehensive documentation and delivering presentations to diverse audiences.

Preferred Qualifications

• Experience working in multicultural and multidisciplinary environments.
• Prior involvement in health or medical education projects.

Application Process

Interested candidates should submit the following documents by 20.4.2026:

1. A detailed CV highlighting relevant experience.
2. A cover letter explaining your interest and suitability for the position.
3. Examples of previous evaluation reports or relevant work (if available).

Submission of Application

Please send your application to eucanscreen.dissemination@dypede.gr with the subject line: Application for External Evaluator.

For any inquiries, please contact [Prof. Apostolos Vantarakis, email: avanta@upatras.gr].

Agenda

Slovenia screening overview and impact.

Presenter: Mojca Gobec

The presentation reviewed Slovenia’s national cancer screening programmes, particularly colorectal and breast cancer screening. Slovenia has achieved high participation and strong integration of screening within the national health system. Breast cancer screening participation reached approximately 77% in 2024, with regional coverage between 73–82%.

The colorectal screening programme has contributed to reductions in colorectal cancer incidence through the detection and removal of precancerous lesions during colonoscopy. This preventive effect, combined with earlier-stage detection, contributes to improved treatment outcomes and survival.

Key success factors highlighted included strong programme leadership, support from the Ministry of Health, engagement of primary care physicians, and the role of nurses in building trust and encouraging participation.

The presentation also noted the favourable political environment and broad support for organised screening programmes in Slovenia. Future discussions include possible expansion to additional screening programmes such as prostate and lung cancer screening.

Presentation

Dutch experience with lung cancer screening.

Presenter: Harry de Koning

This presentation summarised evidence and implementation experience from lung cancer screening programmes in the Netherlands, with reference to the NLST and NELSON trials. Both studies demonstrated that low‑dose CT (LDCT) screening reduces lung cancer mortality and shifts diagnosis toward earlier stages.

LDCT screening frequently detects pulmonary nodules, with nodules appearing in roughly half of baseline scans. To avoid unnecessary diagnostic procedures, the Dutch programme applies a volume‑based nodule management algorithm:

• 100 mm³ – negative
• 100–300 mm³ – indeterminate, requiring surveillance
• ≥300 mm³ – positive, requiring diagnostic follow‑up

Implementation studies reported a positive predictive value of around 40% for referred nodules and referral rates of approximately 2.2% across screening rounds. Risk‑based selection using a questionnaire based on PLCO models was used to identify eligible individuals aged roughly 60–79.

Key implementation challenges include CT capacity, treatment infrastructure, governance structures, and management of incidental findings. Incidental clinically relevant findings occur in roughly 2–3% of scans and require clear reporting protocols. Estimated screening costs are around €100–150 per scan, with modelling studies indicating overall cost‑effectiveness.

Presentation

Capacity building activities in EUCanScreen

• • Task 11.3 Training and audit of colonoscopies.

Presenter: Jaroslaw Regula

Task 11.3 focuses on improving the quality of colonoscopy training by training experienced endoscopists to become effective trainers. The programme emphasises “teaching the teachers” rather than teaching technical colonoscopy skills directly.

Courses are small, with approximately eight participants, and run as two‑day interactive programmes combining theoretical teaching, simulation models, and supervised clinical practice.

Evidence from a prior randomized controlled trial indicates that such trainer education can significantly improve adenoma detection rates (ADR), with sustained effects observed for up to two years.

Four courses are planned within the programme. The first course was recently held in Oslo and additional courses are scheduled later in the year.

Presentation

• Task 11.4 Training and audit of upper endoscopies.

Presenter: Mario Dinis Ribeiro, Patricia Sousa Alves

The ELK & Screen training programme focuses on improving the quality of upper gastrointestinal endoscopy training using a blended learning model.

The programme includes asynchronous webinars, synchronous online sessions, peer‑review activities, and face‑to‑face workshops. Three course editions are planned with in‑person sessions in Porto and Kaunas.

Approximately 80 applicants from 24 countries applied to participate. Participants are primarily gastroenterologists with responsibilities for training within their institutions.

Peer‑review activities included assessment of 95 submitted endoscopy videos. Accreditation processes are ongoing and the programme is supported by the European Society of Gastrointestinal Endoscopy (ESGE). Upcoming milestones include in‑person sessions in Porto and Kaunas, followed by post‑course evaluation and testing.

Presentation

• Task 11.5 Cervical cancer screening specialist training and regional training centre.

Presenter: Hilde K. S. Underthun

Task 11.5 aims to strengthen colposcopy training through a train‑the‑trainer approach. The programme uses a blended training format including preparatory reading, online sessions, and in‑person workshops.

Courses have been delivered in several countries including Norway, Latvia, and Slovenia. The training focuses on developing trainer competencies and introducing structured feedback methods.

Participants receive practical tools such as a laminated feedback framework to support implementation of training activities in their own clinical settings.

Future activities include development of a comprehensive colposcopy course package for the learning platform, specialist training courses, and multidisciplinary training workshops aimed at improving quality assurance and guideline implementation

Presentation

• Task 11.6 Training and audit of the quality of low-dose CT (LDCT) scans: a regional (LDCT) training centre.

Presenter: Zsuzsanna Mikos

Task 11.6 focuses on strengthening capacity for LDCT lung cancer screening through radiologist training and quality assurance activities.

Nine three‑day training courses for radiologists have been organised in Budapest, Florence, and Kaunas, with 94 participants from 15 countries. The courses combine lectures with hands‑on interpretation of CT scans.

A Central European Training Centre in Budapest is being developed to support future training activities. Additionally, an accredited online course on LDCT screening is available on the WHO learning platform.

The team is developing an audit handbook defining quality criteria for LDCT screening programmes, with the first draft expected in September. Two expert webinars are also planned addressing incidental findings and cardiovascular findings in chest CT.

Presentation

Summary and information on other WP11 activities.

Presenter: Dana Coza

Work Package 11 coordinates multiple training initiatives across different cancer screening domains. Seven specialised training programmes have been established covering both established and emerging screening modalities.

Training formats include face‑to‑face, blended learning, and online courses. The programme aims to train approximately 572 participants through face‑to‑face or blended formats, while online courses have no capacity limits.

In the previous year, 156 participants were enrolled across WP11 courses. Leadership training activities are also planned, including workshops scheduled for 2027 and 2028 based on a rapid review conducted in collaboration with WHO experts.

The work package also supports regional training centres and aims to ensure sustainability of training programmes beyond the duration of the joint action.

Presentation

Consolidated EU Barrier Assessment tool (T4.3)

Presenters: Kayo Togawa, Silvia Deandrea

This session presented the consolidated barrier assessment framework developed under Task 4.3. The tool integrates three existing approaches: a PRECEDE‑PROCEED–based screening planning model, the Intervenor web tool for barrier assessment and interventions, and Utopia East implementation roadmaps.

The resulting tool, called UCAN Stream, is an Excel‑based strategic planning instrument designed to support countries in identifying barriers to screening implementation and selecting appropriate interventions.

The tool assesses 81 system‑level barriers and helps users link barriers to evidence‑based interventions and implementation strategies. Outputs include visual analyses based on the Tanahashi framework to identify bottlenecks in service coverage.

The tool is currently undergoing pilot testing in several countries. Results and user feedback will be used to refine the methodology and finalise the toolkit. given.

Presentation

Toolkit and the data platform for toolkit.

Presenter: Mari Nygard

This presentation introduced the EUCanScreen implementation toolkit designed to support cancer screening programmes in improving participation and reducing inequalities.

The toolkit is intended to provide practical implementation resources rather than simply presenting information. Planned resources include templates, communication strategies, training materials, checklists, dashboards, and multimedia tools.

The European Cancer Leagues organisation was selected as the long‑term host for the toolkit. The platform will include search functionality, multilingual content, modular design, and potentially AI‑supported literature querying tools.

The toolkit aims to support policymakers, screening programme managers, and public health organisations in translating evidence into practical programme improvements.

Presentation

WHO data platform to host the training programmes.

Presenter: Anouk Berger

The WHO Academy learning platform hosts several EUCanScreen training courses, including public courses on lung cancer screening and additional cohort‑based courses under development.

However, technical constraints related to authentication and reviewer anonymity have created challenges for accreditation processes, particularly with the European Accreditation Council for Continuing Medical Education.

The consortium is considering a joint letter to accreditation organisations requesting adapted procedures for reviewing courses hosted on the WHO platform.

Platform support staff changes were also announced, and coordination with task leaders will continue to ensure smooth implementation of training programmes.

Presentation

MAS-AI tool (T4.4)

Presenter: Iben Fasterholdt

The MAS‑AI (Model for Assessing Artificial Intelligence) tool supports decision‑makers in evaluating AI technologies for healthcare systems. The model provides a structured framework for assessing clinical, organisational, economic, and ethical aspects of AI implementation.

The EUCanScreen project is adapting the MAS‑AI framework for the European context. Development activities have included expert workshops and Delphi consultations involving consortium partners and external experts.

A draft scientific publication describing the updated model is currently under review, and the tool is expected to support evidence‑based procurement and implementation decisions for AI technologies in screening and healthcare services.

Presentation

Task meeting feedback and first reflections after financial report submission.

Presenter: Iveta Enina

Project announcements, periodic reporting requirements, and financial updates.

Presentation

Status of the publication and scientific presentation reporting. Summary on the key upcoming events.

Presenter: Marcis Leja

The session emphasised the importance of systematically reporting all scientific outputs generated within the project, including peer-reviewed manuscripts, conference presentations, posters, and PhD theses. Participants acknowledged that current reporting is incomplete, with only six full-text manuscripts formally logged, indicating that additional outputs exist but have not yet been captured. All materials should be uploaded to the SharePoint outputs log in standardised formats (PDF or presentation slides) to ensure traceability, enable technical review, and support accurate project-level reporting and evaluation.

Manuscript coordination is currently managed centrally, with Yelena leading operational activities. Partners are encouraged to actively collaborate, share draft manuscripts, and align with internal review processes. In addition, partners were reminded to inform the project coordinator about planned conference participation and submitted abstracts, and to consult the project webpage for updates on upcoming events and dissemination opportunities.

Presentation

WP2 Update

Presenter: Apostolos Vantarakis

WP2 presented an overview of dissemination objectives and ongoing activities, including the development of the project identity, video and podcast materials, and regular coordination through dissemination and communication committee meetings. Website and newsletter analytics were reviewed, highlighting persistent gaps in KPI reporting and relatively low engagement levels, particularly across social media channels. Few countries and competent authorities have not yet submitted required KPI data, limiting the ability to assess dissemination performance and overall impact. Partners were strongly encouraged to provide missing data and to increase their engagement in dissemination activities. The project is currently in the data collection and reporting phase, with an interim report planned for submission at the end of July. An internal review period is scheduled from 18 May to 8 June, during which work package representatives are expected to provide structured feedback. The team confirmed completion of the brand book and initial campaign materials, including interviews and video production. With a success, a structured monthly country-focused campaign has been introduced, incorporating new dissemination tools as storytelling elements such as ‘meet the people’. Special emphasis was placed on ensuring accessibility, inclusivity, and cultural sensitivity of all communication outputs, as well as on developing sustainability strategies to maintain dissemination activities beyond the project’s duration.

Efforts to establish synergies with other projects are ongoing, although response rates remain limited. Discussions addressed potential collaboration formats, including both formal agreements and informal cooperation mechanisms.

Presentation

WP5 Update

Presenter:Tytti Sarkeala, Carlo Senore

WP5 focuses on improving data harmonisation, developing open-source monitoring tools, and enabling cross-border research in alignment with the European Health Data Space (EHDS). A comprehensive survey was conducted across 27 countries (with 26 confirmed responses at the time of reporting and additional responses expected), aiming to map legal frameworks, data availability, linkage capabilities, and monitoring practices. The survey revealed substantial heterogeneity across countries.

Approximately 65% of respondents reported the existence of national health data legislation, while only 27% indicated the presence of screening-specific legal frameworks. Regarding data linkage, 68% of countries reported the ability to link screening data with cancer registries, and 56% reported linkage with mortality registries, although practical implementation varies. Consent models differ considerably: around 50% of countries reported no active consent requirement, 19% operate under opt-out systems, and approximately 15% require explicit opt-in consent, reflecting diverse regulatory and ethical approaches. Countries have implemented measures to reduce access barriers, including free screening services (reported in approximately 80% of cases), multilingual communication materials (around 50%), and the use of community mediators (approximately 30–40%). However, information systems remain fragmented in many settings and are often not fully integrated across clinical pathways. In particular, many systems lack linkage to diagnostic outcomes, staging information, and treatment initiation data, limiting their usefulness for monitoring and evaluation.

Routine data stratification is commonly performed by age and sex (around 70% of countries) and by geographic area (approximately 65–89%), but stratification by socioeconomic status, country of birth, or individual risk factors remains limited (generally below 20%). As a result, around 80% of screening programme evaluations do not adequately assess social inequalities.

To address these gaps, WP5 has developed an R-based monitoring package and a first set of harmonised indicators. A phased pilot implementation is planned, including preparation and onboarding (April), technical setup (May), testing (June), and broader rollout after the summer. Countries and organisations were invited to participate in the piloting phase and to validate survey findings, particularly in cases where regional variability or interpretation issues may affect data accuracy.

Presentation

WP6 Update

Presenter: Mari Nygard

WP6 presented ongoing work on identifying and addressing barriers and facilitators to cancer screening participation. A key development is the creation of a web-based tool using large language models to synthesise stakeholder input and generate structured insights. Systematic reviews covering colorectal, breast, and cervical screening identified common barriers such as lack of time, insufficient knowledge, fear, cultural factors, and mistrust. Facilitators include improved information provision, positive screening experiences, and perceived health benefits.

The work package is also developing targeted interventions for vulnerable populations, including migrants and individuals with intellectual disabilities, using culturally adapted materials and tailored communication strategies. Randomised trial protocols have been prepared and are currently undergoing ethical review. These studies aim to evaluate the effectiveness of different communication approaches, including the role of social media in increasing participation rates.

Additional work focuses on inclusion of gender minorities and improvement of health literacy, with plans to develop practical tools and guidance for implementation in screening programmes.

Presentation

WP7 Update

Presenter: Gemma Binefa Rodriguez, Marcos Castejon Suner

WP7 presented a comprehensive set of activities focusing on quality assurance, data harmonisation, and the integration of artificial intelligence in cancer screening.

A structured quality review of 182 screening information materials across countries assessed dimensions such as transparency, completeness, readability, and presentation. The results showed consistently low transparency scores, highlighting gaps in communicating benefits, risks, and uncertainties to target populations. Country-level results were shared with partners for validation and benchmarking.

A Europe-wide quality assurance survey has been completed, with follow-up interviews planned to clarify regional inconsistencies and better understand organisational differences in screening delivery. Task 7.2 focused on interval cancer definitions and reporting. Separate working groups for colorectal, breast, and cervical screening completed literature reviews, identifying substantial heterogeneity in definitions, denominators, and registry practices. A modified Delphi process and consensus meetings are planned for 2026 to establish harmonised definitions and multi-level performance indicators.

Task 7.3 is developing a white paper on responsible and scalable implementation of artificial intelligence in screening programmes. The draft is currently under internal review, and consortium members are invited to nominate stakeholders for validation and provide country-specific perspectives.

Task 7.4 reported completion of multiple surveys on invitation strategies and progress in literature review, with data analysis ongoing and publications expected in later phases.

Task 7.5 is progressing from conceptual decision-aid models to the development of a web-based decision aid builder. The platform will include templates, co-creation functionalities, and dashboards for monitoring use and outcomes. Key challenges include regulatory classification (e.g., potential medical device status), integration into existing health systems, and ensuring accessibility and usability across diverse populations.

Presentation

WP8 Update

Presenter: Ildiko Toth

WP8 focuses on expanding cancer screening to lung, gastric, and prostate cancers through harmonised methodologies and pilot implementations.

A comprehensive white book is under development, with organ-specific sections (~50 pages each) and contributions from multiple partners, alongside an interim report expected in May. Work builds on previous initiatives such as TOGAS, with additional efforts to define quality indicators and harmonise data collection across heterogeneous data sources.

A multilingual data platform is being developed, including standardised consent forms and data definitions, with support from an external subcontractor. The EUGastScreen pilot will evaluate the feasibility of combined gastric and colorectal screening using remote testing and Helicobacter pylori detection followed by eradication therapy. The pilot involves several countries (e.g., Estonia, Italy, Latvia, Portugal), with the possibility of additional sites joining subject to local funding. Operational challenges identified include sample collection logistics, test accuracy, and seasonal effects on sample transport and processing.

In addition, Task 8.5 integrates intensive smoking cessation interventions into lung cancer screening programmes. Randomised pilot studies are currently ongoing in Finland and Hungary, with harmonised protocols and recruitment conducted between February and May 2026.

Presentation

WP9 Update

Presenter: Paola Mantellini

WP9 focuses on advancing risk-based cancer screening and supporting its implementation across member states.

A large umbrella survey collected 64 responses from 21 countries, highlighting ongoing and planned risk-based screening activities across multiple cancer types, particularly breast and cervical screening. A complementary communication survey covering 33 countries identified commonly used tools, including websites, tailored invitation letters, leaflets, SMS reminders, and decision aids. Interviews with 11 cervical screening pilot programmes have been completed, providing insights into algorithms, risk thresholds, organisational structures, legal frameworks, and IT/data management challenges. Further interviews are planned for colorectal screening initiatives.

The WP is transitioning towards qualitative research using focus groups. Five cancer-specific focus groups (breast, colorectal, cervical, lung, prostate) will be conducted using purposive sampling (6–8 participants per group), covering both participants and informed non-participants. The aim is to explore perceptions, acceptability, and informed decision-making related to risk-based screening. Data analysis will follow a combined deductive and inductive thematic approach, using shared codes and themes across countries, while reporting will remain at country level without sharing transcripts.

A comprehensive implementation toolbox is being developed, integrating evidence from surveys, interviews, systematic reviews, and focus groups, with plans to apply consensus methods to prioritise tools and recommendations for member states.

Presentation

WP10 Update

Presenter: Iris Lansdorp – Vogelaar

WP10 presented modelling work aimed at supporting evidence-based screening policy decisions.

Models have been calibrated across multiple countries and cancer types, showing good alignment with observed data. Risk-based screening approaches may significantly reduce the target population, thereby improving efficiency and cost-effectiveness. Gastric cancer modelling identified strategies that balance effectiveness and cost, while also highlighting potential risks associated with antimicrobial resistance.

Preliminary analyses of multi-cancer early detection technologies suggest only modest additional benefits compared to existing screening methods and highlight uncertainties regarding performance. The findings support a cautious approach and do not currently justify replacing established screening programmes.

Presentation

WP3 Update

Presenter:Ludwig Grillich

WP3 presented evaluation activities, acting as a ‘critical friend’ to assess overall project performance, implementation, and accountability.

The consortium is currently in the data collection phase, with an interim report scheduled for July.

Survey results indicate generally positive perceptions of project progress, but the response rate remains low (approximately 20%), limiting representativeness. Identified challenges include communication gaps, uneven engagement across partners, and resource constraints. Planned actions include targeted mini-surveys and SWOT workshops to strengthen governance, improve feedback mechanisms, and support strategic planning.

Presentation

WP4 Update

Urska Ivanus, Paolo Giorgi Rosso, Kayo Togawa, Andre Carvalho

WP4 focuses on ensuring the long-term sustainability and effective implementation of EUCanScreen project outcomes beyond the duration of the joint action. The work package addresses both strategic and operational dimensions of sustainability, including stakeholder engagement, capacity building, and integration of project results into national screening programmes.

A central component of WP4 is the development of a structured stakeholder network, designed to support dissemination, implementation, and policy uptake of project results. The network is intended to function in an advisory capacity, complementing existing governance structures such as the governmental advisory board. It will include representatives from European institutions (e.g., European Commission Directorates), international organisations (e.g., WHO Europe, IARC), national health authorities, and relevant professional and digital health stakeholders. Regular meetings (approximately every six months) are planned to ensure continuous engagement and feedback.

WP4 also emphasises the importance of aligning sustainability activities with existing dissemination and stakeholder mapping efforts, particularly those conducted under WP2. An updated stakeholder mapping database is maintained and will be regularly revised to ensure coordination across work packages and to support targeted communication strategies.

WP4 also introduced conceptual work on sustainability, including a framework linking screening intensity and country resource levels to sustainability risks. This approach highlights that high-intensity screening programmes implemented in low-resource settings may face significant long-term sustainability challenges, underlining the importance of context-sensitive implementation strategies.

In addition, WP4 is developing practical sustainability support tools, including workshops, guidance materials, and a web-based learning platform, partly building on outputs from WP11 and collaboration with international partners such as IARC. These tools aim to facilitate knowledge transfer, support capacity building, and ensure that project innovations can be maintained and scaled after project completion.

Overall, WP4 plays a critical role in bridging technical project outputs with real-world implementation, ensuring that results are not only generated but also effectively adopted, maintained, and integrated into European cancer screening systems.

Presentation

Status of the surveys and data collection

Presenter:Tala Haddad

The session provided an overview of the current status of surveys and data collection activities across the project. Participants noted that, despite ongoing efforts, awareness of active surveys remains limited among some consortium members, leading to missed participation opportunities.

To address this issue, a proposal was made to introduce a publicly accessible overview table on the project website, listing all ongoing surveys, relevant links, and associated documentation. This would improve transparency and facilitate broader engagement across partners.

It was confirmed that an internal tracking table of survey activities already exists within the project. This table includes detailed information on survey status, timelines, and responsible work packages, and can be shared more widely within the consortium to improve coordination.

At the same time, it was clarified that detailed survey results will remain restricted to the internal project environment (project console) and will not be made publicly available, in order to ensure data protection and appropriate use of sensitive information.

Overall, the discussion highlighted the need for improved communication and visibility of data collection activities, as well as better coordination across work packages to maximise participation and data completeness.

Presentation

Update on the Stakeholder Network

Presenter: Marcis Leja

The session provided an update on the development of the EUCanScreen stakeholder network, which is being established under WP 4 to support dissemination, implementation, and policy uptake of project results.

The stakeholder network is designed as an advisory, non-binding structure, distinct from the governmental advisory board. Its main role is to provide expertise, facilitate communication, and support the translation of project outcomes into practice across European cancer screening systems.

The network will include a broad range of stakeholders, such as representatives from European institutions (including relevant European Commission Directorates), international organisations (e.g., WHO Europe, IARC), national health authorities, professional organisations, and actors involved in digital health and screening infrastructure.

An existing stakeholder mapping database—initially developed under WP2—is being further expanded and will be regularly updated (approximately every six months). This mapping aims to ensure coordinated engagement, avoid duplication of efforts, and support targeted dissemination activities across work packages.

A major planned activity is a European stakeholder conference, tentatively scheduled in Rome. The event is intended to engage high-level policymakers and decision-makers and will include parallel workshops aligned with core work packages. The primary objective of the conference is dissemination of project results, while also fostering collaboration and policy dialogue.

However, several challenges were identified, including budget limitations, uncertainties regarding travel support for participants, and the need to clearly define the target audience. Discussions emphasised that the event should prioritise policy-level stakeholders rather than purely technical audiences.

Additional considerations included potential collaboration with other European projects and funding initiatives (e.g., DG Connect), as well as careful handling of industry involvement, which should remain limited and clearly separated from policy-focused discussions.

Overall, the discussion highlighted the importance of strategic stakeholder engagement, clear positioning of the network, and strong coordination across work packages to maximise the long-term impact of the project.

Presentation

Implementation of Decision Aids in cancer screening programmes.

Presenter: Montse Garcia, Cinzia Colombo, Marcos Castejon Suner

The meeting transitioned to a workshop under Task 7.5 focusing on the implementation determinants of web-based decision aids in cancer screening programmes. The session was organised in a hybrid format and actively engaged consortium members in interactive discussion.

The presenters summarised findings from an extensive literature review, which identified only a limited number of relevant studies. This highlighted a significant evidence gap and underscored the need to draw on consortium expertise to identify key barriers and facilitators for the implementation of web-based decision aids.

Clear instructions were provided for participation in the hybrid workshop format. The session utilised Slido as an interactive tool to collect input from participants. Attendees were asked to use their own devices to access questions and thematic prompts.

Participants were invited to respond from the perspective of their own screening context and to submit individual contributions in a structured format. Each response was required to include a single idea, specify whether it represented a barrier or a facilitator, and indicate the relevant screening programme. Multiple submissions were encouraged to capture a broad range of perspectives.

Agenda

Cancer Screening Implementation

The EUCanScreen project successfully convened its consortium meeting on 11-12 March 2026, bringing together partners and stakeholders both in person in Bled, Slovenia, and online. The two-day event provided a vital forum for reviewing project progress, sharing valuable insights, and strategizing for the future of cancer screening implementation across Europe.

Meeting Agenda Recap

Day 1 | Wednesday, 11 March 2026

Focus: Welcome, Good Practices, and Project Tools

The first day commenced with a warm welcome from our Slovenian hosts and a special greeting from the Ministry of Health of Slovenia. The afternoon session featured:

• Good Practices in Screening: Presentations on Slovenia’s high screening coverage and the Dutch experience with lung cancer screening.

• Project Progress: Updates on capacity-building activities (WP11) and the consolidated EU Barrier Assessment Tool (T4.3).

• Innovative Tools: Introductions to the project’s data platform, the WHO Academy learning platform, and the new MAS-AI Tool (T4.4).

• Networking: A productive coffee break and a working dinner allowed for valuable connections among participants.

•  

Day 2 | Thursday, 12 March 2026

Focus: Work Package Updates, Sustainability, and Future Steps

The second day provided a comprehensive overview of the project’s scientific and operational progress:

• Work Package Updates: Detailed presentations from Work Package leaders (WP2 through WP10), covering the latest developments and findings.

• Sustainability and Outreach: A session on planning sustainability workshops, an update on the Stakeholder Network, and the status of surveys and data collection.

• Special Session: An in-depth discussion on the “Implementation of Decision Aids in cancer screening programmes.”

• Planning: A meeting of the Scientific Committee to guide the project’s next phases.

• Closing: A group photo, lunch, and final wrap-up preceded the concluding working dinner.

Key Sessions & Topics

Over the two days, the consortium delved into critical topics, including:

• Capacity Building: Updates on training activities and programs.

• Data & Tools: Presentations on the data platform, barrier assessment tool, and the MAS-AI tool.

• Implementation Science: Discussions on decision aids and real-world screening program implementation.

• Project Management: Financial reporting, publication status, and summaries of upcoming events.

The EUCanScreen consortium thanks all participants for their contributions to a successful and productive meeting.

Agenda

Work Package 4 (WP4) Kick-off Meeting

From 9 to 11 March 2026, partners of the EUCanScreen project gathered in Bled, Slovenia (among the supportive countries), for the Work Package 4 (WP4) Kick-off Meeting, focusing on sustainability in cancer screening programmes across Europe.

Hosted at Hotel Park in Bled, the meeting brought together project partners, experts, and representatives from both target and supporting countries to exchange knowledge, identify key challenges, and define priorities for strengthening cancer screening systems in Europe.

Strengthening the Sustainability of Cancer Screening Programmes

The three-day meeting marked the official launch of WP4 activities (led by Slovenia), which aim to support the sustainable implementation, operation, and development of organised, population-based cancer screening programmes across participating countries.

Through a series of mini-talks, poster sessions, and interactive workshops, participants discussed important topics including:

• governance models for cancer screening programmes

• quality and effectiveness of screening across Europe

• cost-effectiveness and long-term sustainability

• barriers affecting the implementation and operation of screening programmes

• opportunities for EU-level collaboration and support

Experts also explored how research, modelling, and data can help inform decision-making and support the development of resilient and sustainable screening systems.

Sharing Experiences Across Europe

A key component of the meeting was the poster sessions, where representatives from target countries — Estonia, Hungary, Romania, Slovakia, Slovenia, and Ukraine — presented the current state of cancer screening governance and sustainability in their national contexts.

Supporting countries, including Denmark, Finland, Ireland, Italy, the Netherlands, Sweden and Slovenia, also shared their experiences and best practices, highlighting successful approaches that could help strengthen screening programmes across Europe.

These discussions helped identify common challenges, priority areas for support, and opportunities for collaboration within the framework of the EUCanScreen project.

Defining Priorities and Next Steps

The meeting also included a prioritisation workshop, where participants worked in breakout groups to identify key actions needed to improve the sustainability of cancer screening programmes. The outcomes of these discussions will help guide the Targeted Support Mechanism (TSM) and the next phases of WP4 activities.

The final sessions focused on aligning expectations between target and supporting countries and planning the next steps for collaboration and implementation within the project.

Moving forward together

The WP4 Kick-off Meeting represented an important milestone for the EUCanScreen project, strengthening collaboration among partners and laying the groundwork for future work aimed at improving cancer screening programmes across Europe.

By fostering dialogue, knowledge exchange, and joint planning, EUCanScreen continues to support more effective, sustainable, and equitable cancer screening systems, ultimately contributing to improved cancer prevention and early detection throughout Europe.

Agenda

The EUCanScreen Consortium Event 2026 will take place on 11–12 March in Bled, Slovenia, bringing together partners from across Europe working to strengthen cancer screening programmes and improve public health outcomes.

Organised within the framework of the European Joint Action on Cancer Screening, the meeting will provide an opportunity for collaboration, knowledge exchange and updates on key project activities. Participants will discuss progress across several work packages and explore innovative tools and approaches that support the implementation of effective cancer screening programmes across Europe.

Agenda Highlights

The programme includes a range of presentations and discussions focusing on:

Best Practice Exchange

• Slovenia’s high screening coverage
• The Dutch experience with lung cancer screening

Technical Innovations

• The Consolidated EU Barrier Assessment Tool
• The MAS-AI Tool supporting screening implementation

Capacity Building

• EUCanScreen training and capacity building activities
• The WHO Academy learning platform

Project Progress Updates

• Presentations on the progress of Work Packages (WP2–WP11) and ongoing project activities.

Online Participation

Stakeholders and interested participants are welcome to join the sessions online via Microsoft Teams.

Day 1 (11 March, 13:30–18:00 CET)

Day 2 (12 March, 9:00–18:00 CET)

Ireland is delighted to present the EUCanScreen project, in its capacity as the spotlight country during the month of December, 2025.

The goal of EUCanScreen is to coordinate research initiatives on population-based cancer screening programmes in Europe. To that end, the Department of Health (DoH), the Health Service Executive’s National Screening Service (NSS) and the Royal College of Surgeons in Ireland (RCSI) are collaborating across all Work Packages of this Joint Action alongside the International Agency for Research on Cancer (IARC), part of the World Health Organization.

Throughout the month, Ireland will spotlight equity in cancer screening, showcasing innovative initiatives designed to improve access and participation in screening.

Follow along as we share information on Ireland’s role in EUCanScreen, featuring posts from it’s partner organisations on their contributions to the Joint Action, and provide updates on Ireland’s involvement in other European cancer screening research projects.